ReviewJournal of neurology2021
Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.Clinical neurology and neurosurgery · 2022Pooled it
- Short-term ambient temperature increases are associated with higher mortality in amyotrophic lateral sclerosis: a case-crossover study of weather conditions.Frontiers in aging neuroscience · 2026Article
- Exploring the Role of Telemedicine in Duchenne Muscular Dystrophy: Benefits and Challenges.JMIR formative research · 2025Article
- The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study.Virology journal · 2025Article
- Update on recent advances in amyotrophic lateral sclerosis.Journal of neurology · 2024Review
- A Mobile Health App to Support Home-Based Aerobic Exercise in Neuromuscular Diseases: Usability Study.JMIR human factors · 2024Article
- Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.Journal of inflammation research · 2024Article
- Effects of the COVID-19 Pandemic on SMA Screening and Care: Physician and Community Insights.Neurology and therapy · 2023Article
- Article
- Heart Failure Post-SARS-CoV-2 Infection in Children with Duchenne Muscular Dystrophy: The Additive Value of Cardiovascular Magnetic Resonance.Children (Basel, Switzerland) · 2023Article
- Article
- Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.Frontiers in immunology · 2023Article
- A Case of COVID-19 With Myasthenic Crisis.Cureus · 2022Article
- Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.Neurology international · 2022Article
- Telemedicine applied to neuromuscular disorders: focus on the COVID-19 pandemic era.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2022Article
- Clinical condition, resuscitation and medical-psychological care of severe COVID-19 patients (part 1).Annales medico-psychologiques · 2022Article
- TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.Acta clinica Croatica · 2022Review
- The relationship between myasthenia gravis and COVID-19: a systematic review.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Review
- Impact of COVID-19 on the quality of life of patients with neuromuscular disorders in the Lombardy area, Italy.Muscle & nerve · 2021Article
- COVID-19 in children with neuromuscular disorders.Journal of neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel Coronavirus disease-19 (COVID-19) pandemic has posed several challenges for neuromuscular disorder (NMD) patients. The risk of a severe course of SARS-CoV-2 infection is increased in all but the mildest forms of NMDs. High-risk conditions include reduced airway clearance due to oropharyngeal weakness and risk of worsening with fever, fasting or infection Isolation requirements may have an impact on treatment regimens administered in hospital settings, such as nusinersen, glucosidase alfa, intravenous immunoglobulin, and rituximab infusions. In addition, specific drugs for SARS-CoV2 infection under investigation impair neuromuscular function significantly; chloroquine and azithromycin are not recommended in myasthenia gravis without available ventilatory support and prolonged prone positioning may influence options for treatment. Other therapeutics may affect specific NMDs (metabolic, mitochondrial, myotonic diseases) and experimental approaches for Coronavirus disease 2019 may be offered "compassionately" only after consulting the patient's NMD specialist. In parallel, the reorganization of hospital and outpatient services may change the management of non-infected NMD patients and their caregivers, favouring at-distance approaches. However, the literature on the validation of telehealth in this subgroup of patients is scant. Thus, as the first wave of the pandemic is progressing, clinicians and researchers should address these crucial open issues to ensure adequate caring for NMD patients. This manuscript summarizes available evidence so far and provides guidance for both general neurologists and NMD specialists dealing with NMD patients in the time of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.